QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

TXG

QT6110x Genomics, Inc.
NASDAQ·Healthcare·Medical - Healthcare Information Services·USA
Latest market price
34.76
+2.63+8.19%
OverviewShort InterestFilings
TXGQT6110x Genomics, Inc.·NASDAQ
OverviewShort InterestFilings
34.76+8.19%
TA
Loading chart...
Screen all →
GEHC+0.72%$61.59VEEV-1.00%$153.30BTSG+2.82%$66.25TEM+4.20%$50.84HQY-1.30%$85.21HNGE+3.55%$69.42DOCS+0.05%$20.46PRVA+1.11%$23.67
Snapshot
Index-P/E-EPS (ttm)
-0.17
Insider Own7.87%
Shs Outstand126.96M
Perf Week19.66%
Market Cap4.08BForward P/E-EPS next Y-0.64Insider Trans-0.02%Shs Float-Perf Month55.94%
Enterprise Value3.81BPEG-EPS next Q-0.23Inst Own-Short Float-Perf Quarter89.12%
Income-22382814.00P/S6.61EPS this Y-347.58%Inst Trans-Short Ratio-Perf Half Y121.26%
Sales638.78MP/B5.24EPS next Y15.83%ROA-2.23%Short Interest-Perf YTD113.12%
Book/sh6.41P/C33.39EPS next 5Y-ROE-2.86%52W High35.65 -2.50%Perf Year229.17%
Cash/sh4.25P/FCF34.57EPS past 3/5Y-ROIC-4.24%52W Low10.38 234.87%Perf 3Y-
Dividend Est.-EV/EBITDA40.88Sales past 3/5Y7.61% 16.55%Gross Margin69.60%Volatility4.62% 4.92%Perf 5Y-
Dividend TTM-EV/Sales5.97EPS Y/Y TTM88.82%Oper. Margin-6.06%ATR (14)2.22Perf 10Y-
Dividend Ex-Date-Quick Ratio5.42Sales Y/Y TTM4.58%Profit Margin-3.55%RSI (14)70.21Recom2.57
Dividend Gr. 3/5Y-Current Ratio5.90EPS Q/Q72.22%SMA2017.95%Beta2.25Target Price22.43
Payout0.00%Debt/Eq0.10Sales Q/Q-2.58%SMA5037.25%Rel Volume1.22Prev Close32.13
Employees1,306LT Debt/Eq0.18EarningsAug 06SMA20081.98%Avg Volume2.96MPrice34.76
IPO DateSep 12, 2019Option/ShortYes / YesEPS/Sales Surpr.65.52% 3.42%Net Debt/EBITDA-4.38Volume3,607,413Change8.19%
Analyst Ratings
DateActionAnalystRatingTarget
May-12-26ReiteratedMorgan StanleyEqual Weight$20 → $22
Apr-14-26ReiteratedBarclaysOverweight$22 → $30
Mar-31-26UpgradeWilliam BlairMarket Perform → Outperform
Mar-02-26ReiteratedStifel Nicolaus$20 → $25
Feb-20-26ReiteratedUBSNeutral$13 → $20
Feb-13-26ReiteratedDeutsche BankHold$16 → $17
Feb-13-26ReiteratedStifel Nicolaus$15 → $20
Feb-13-26ReiteratedCanaccord GenuityBuy$20 → $22
Jan-12-26ReiteratedNeedham$21
Dec-22-25ReiteratedCanaccord GenuityBuy$16 → $20
Latest News
Jun-17-26
Jun-17-2609:04AM
10x Genomics Partners With Cleveland Clinic Over Research In Novel Diagnostics For Bladder CancerBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue639643611
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A195199196
Gross Profit444444414
Selling, General and Administrative Excl. Other292316344
Research and Development231239265
Other Operating Expense-3900
Operating Income-39-111-195
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-86-71-17
Net Income Before Taxes-19-40-178
Income Taxes345
Consolidated Net Income-21-44-183
Net Income From Continuing Operations-21-44-183
Net Income-21-44-183
EPS (Recurring)-0.17-0.35-1.52
EPS (Basic, Before Extraordinaries)-0.17-0.35-1.52
EPS (Diluted)-0.17-0.35-1.52
EBITDA944-134
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio6.963.17—
Gross Margin69.4869.0567.76
Operating Margin-6.10-17.26-31.91
Net Margin-3.29-6.84-29.95
Shares Outstanding128125120
Market Capitalization4,4492,039—
Operating Lease Expense
———
Insider Trading Volume
$38.42$34.91$31.40$27.90$24.39● Close Price0.00M0.34M0.68M1.02M1.36MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Saxonov SergeChief Executive OfficerMay 26 '26Sale24.7110,718264,8331,138,380May 27 12:00 AM
Hindson Benjamin J.See RemarksMay 22 '26Sale24.4411,595283,399502,000May 27 12:00 AM
Saxonov SergeChief Executive OfficerMay 22 '26Sale24.4418,175444,2241,149,098May 27 12:00 AM
Taich AdamChief Financial OfficerMay 22 '26Sale24.4415,098369,018379,898May 27 12:00 AM
Saxonov SergeChief Executive OfficerApr 14 '26Sale24.565,000122,7841,167,273Apr 16 12:00 AM
Saxonov SergeChief Executive OfficerMar 24 '26Sale19.525,00097,6121,172,273Mar 25 12:00 AM
Saxonov SergeChief Executive OfficerMar 23 '26Sale19.1310,000191,2971,177,273Mar 25 12:00 AM
Saxonov SergeChief Executive OfficerMar 02 '26Sale22.7316,152367,0961,203,667Mar 04 12:00 AM
Teichmann Sarah A.DirectorFeb 25 '26Sale19.417,579147,10826,780Feb 27 12:00 AM
Saxonov SergeChief Executive OfficerFeb 23 '26Sale18.589,632178,9281,061,924Feb 25 12:00 AM
Taich AdamChief Financial OfficerFeb 23 '26Sale18.588,968166,593288,417Feb 25 12:00 AM
Hindson Benjamin J.See RemarksFeb 23 '26Sale18.587,826145,379424,779Feb 25 12:00 AM
Saxonov SergeChief Executive OfficerJan 05 '26Option Exercise1.20100,000120,0001,071,556Jan 07 12:00 AM
Saxonov SergeChief Executive OfficerNov 24 '25Sale19.0013,261251,9361,021,556Nov 25 12:00 AM
Taich AdamChief Financial OfficerNov 24 '25Sale19.0011,888225,852297,385Nov 25 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR